科兴制药(688136) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 45.49% to CNY 46,564,983.61 year-on-year[9] - Operating revenue decreased by 19.81% to CNY 277,043,705.24 compared to the same period last year[9] - Basic earnings per share decreased by 59.65% to CNY 0.23 compared to the same period last year[9] - Diluted earnings per share decreased by 59.65% to CNY 0.23 compared to the same period last year[9] - The net profit attributable to shareholders was CNY 46.57 million, down 45.49% year-on-year[19] - Total revenue for Q1 2021 was $277.04 million, a decrease of 19.7% compared to $345.50 million in Q1 2020[36] - Net profit for Q1 2021 was $46.56 million, a decline of 45.5% from $85.43 million in Q1 2020[37] - Total operating revenue for Q1 2021 was ¥211,863,276.87, an increase of 18.9% compared to ¥178,264,930.81 in Q1 2020[39] - Net profit for Q1 2021 was ¥34,953,076.34, down 11.5% from ¥39,498,303.40 in Q1 2020[40] Assets and Liabilities - Total assets decreased by 1.50% to CNY 2,331,024,937.65 compared to the end of the previous year[9] - The company's total liabilities decreased to CNY 454,339,254.53 from CNY 536,495,748.20, indicating improved financial stability[28] - Current assets totaled CNY 1,498,272,911.20, down from CNY 1,643,921,554.25 at the end of 2020[26] - Cash and cash equivalents decreased to CNY 362,275,497.28 from CNY 1,102,649,871.87, indicating a significant reduction in liquidity[26] - Total liabilities decreased to $430.59 million in Q1 2021 from $530.33 million in Q4 2020, a reduction of 18.8%[32] - The company's total liabilities were 440,700,922.42 RMB, slightly down from 444,038,064.18 RMB at the end of 2020, showing a minor reduction in debt levels[50] Cash Flow - Net cash flow from operating activities increased by 131.60% to CNY 35,705,923.74 year-on-year[9] - Operating cash flow for the period reached CNY 35,705,923.74, an increase of 131.60% compared to CNY 15,417,348.26 in the same period last year[20] - The company's cash and cash equivalents decreased by 732,170,103.95 RMB in Q1 2021, compared to an increase of 18,775,039.27 RMB in Q1 2020, indicating a liquidity challenge[47] - Cash flow from financing activities showed a net outflow of ¥132,592,940.82 in Q1 2021, compared to a net inflow of ¥5,073,118.00 in Q1 2020[44] - Total cash outflow from investing activities was ¥759,794,920.00 in Q1 2021, significantly higher than ¥32,419,269.56 in Q1 2020[44] Research and Development - R&D investment as a percentage of operating revenue increased by 2.51 percentage points to 5.30%[9] - Research and development expenses rose to CNY 146.73 million, an increase of 52.19%, reflecting the company's intensified investment in R&D[18] - Research and development expenses increased to $14.67 million in Q1 2021, up 52.3% from $9.64 million in Q1 2020[36] - Research and development expenses increased to ¥8,692,845.06 in Q1 2021, up 152.8% from ¥3,442,722.07 in Q1 2020[39] Shareholder Information - The number of shareholders reached 15,122 at the end of the reporting period[12] - Total equity attributable to shareholders reached CNY 1,830,120,699.51, remaining unchanged from the previous period[51] Operational Challenges - The company experienced a decline in sales of its core product, human interferon α1b, due to a normalization of demand following the peak during the COVID-19 pandemic[19] - The company faced challenges in overseas sales due to ongoing pandemic conditions affecting product shipments and orders[19] - The overall increase in personnel costs was attributed to an expanded workforce and optimized personnel structure[19] - The company reported a significant decrease in income tax expenses, down 71.42% to CNY 6.07 million, influenced by a lower tax rate for subsidiaries and increased R&D deductions[19] Other Financial Metrics - The company reported a gross profit margin of approximately 18.1% for Q1 2021, down from 20.5% in Q1 2020[36] - The company executed a new leasing standard adjustment, impacting the financial statements, although specific financial implications were not detailed[48]